GEOVAX, INC.
Viral vector vaccine platform (GV-MVA-VLP) for COVID-19 using modified vaccinia virus and virus-like particles with novel antigen design to prevent antibody-dependent enhancement
- Sector
- Biotech
- Total capital
- $3.4M
- Federal grants
- $3.2M
- 8 awards · 2015–2021
- Rank in peer group#306 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $198K
- 1 award · Health and Human S
- Rank in Biotech#297 of 4373
- Granted patents
- 13
- 27 pending · first 2021
- Rank in peer group#18 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19$300K
- Federal grantHealth and Human S · Phase I · Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus$300K
- Federal grantHealth and Human S · Phase I · Construction and efficacy testing of novel recombinant vaccine designs for eliciting both broadly neutralizing antibodies and T cells against Lassa virus$300K
- Federal grantHealth and Human S · Phase I · Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus$300K
- Federal grantHealth and Human S · Phase II · Enhancing protective antibody responses for a DNA/MVA HIV vaccine$658K
- Federal contractHealth and Human S · Igf::ot::igf Stage Vaccine Development$198K
- Federal grantHealth and Human S · Phase I · Directed Lineage Immunizations for Eliciting Broadly Neutralizing Antibody$294K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase II · Enhancing protective antibody responses for a DNA/MVA HIV vaccine$740K
- Federal grantHealth and Human S · Phase I · Directed Lineage Immunizations for Eliciting Broadly Neutralizing Antibody$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#18 · top 4%
- Linked publications#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 13 granted of 40- GrantedVaccines And Uses Thereof To Induce An Immune Response To SARS-COV2USPTOUS 12,577,589
- GrantedReplication-deficient Modified Vaccinia Ankara (mva) Expressing Marburg Virus Glycoprotein (gp) And Matrix Protein (VP40)USPTOUS 12,370,249
- GrantedCompositions And Methods For Generating An Immune Response To Treat Or Prevent MalariaUSPTOUS 12,329,808
Show all 40 patent records
- Vaccines And Uses Thereof To Induce An Immune Response To SARS-COV2Mar 17, 2026 · US 12,577,589Granted
- Replication-deficient Modified Vaccinia Ankara (mva) Expressing Marburg Virus Glycoprotein (gp) And Matrix Protein (VP40)Jul 29, 2025 · US 12,370,249Granted
- Compositions And Methods For Generating An Immune Response To Treat Or Prevent MalariaJun 17, 2025 · US 12,329,808Granted
- Vaccinia Viral Vectors Encoding Chimeric Virus Like ParticlesMar 11, 2025 · US 12,247,214Granted
- Multivalent Hiv Vaccine Boost Compositions And Methods Of UseFeb 13, 2024 · US 11,897,919Granted
- Replication-deficient Modified Vaccinia Ankara (mva) Expressing Marburg Virus Glycoprotein (gp) And Matrix Protein (VP40)Feb 13, 2024 · US 11,896,657Granted
- Compositions And Methods For Generating An Immune Response To Treat Or Prevent MalariaJan 2, 2024 · US 11,857,611Granted
- Immuno-oncology Compositions And Methods For Use ThereofAug 17, 2023 · Application 17950989Pending
- Replication-deficient Modified Vaccinia Ankara (mva) Expressing Ebola Virus Glycoprotein (gp) And Matrix Protein (VP40)Jul 18, 2023 · US 11,701,418Granted
- Method For Generating A Zikv Immune Response Utilizing A Recombinant Modified Vaccina Ankara Vector Encoding The NS1 ProteinMay 2, 2023 · US 11,638,750Granted
- Vaccinia Viral Vectors Encoding Chimeric Virus Like ParticlesAug 16, 2022 · US 11,413,341Granted
- Cancer Vaccine Compositions And Methods For Use ThereofMay 26, 2022 · Application 17542100Pending
- Compositions and Methods for Generating an Immune Response to Treat or Prevent MalariaApr 26, 2022 · US 11,311,612Granted
- Compositions and Methods for Generating an Immune Response to a Tumor Associated AntigenMar 22, 2022 · US 11,278,607Granted
- Multivalent HIV Vaccine Boost Compositions and Methods of UseAug 24, 2021 · US 11,098,086Granted
- Immuno-Oncology Compositions and Methods for Use ThereofJul 22, 2021 · Application 16641728Pending
- Compositions and Methods for Generating an Immune Response to LASVJun 4, 2020 · Application 16631489Pending
- Compositions and Methods for Generating an Immune Response to a FlavivirusJan 31, 2019 · Application 16074947Pending
- Mva Vectors Expressing Polypeptides And Having High Level Production In Certain Cell LinesOct 24, 2013 · Application 13655294Pending
- Method Of Increasing Immune Response To Hiv AntigensApplication PCTUS2014047056Pending
- Mva Vectors Expressing Polypeptides And Having High Level Production In Certain Cell LinesApplication PCTUS2012060878Pending
- Single-dose Mva Vaccines For Protection Against OrthopoxvirusApplication PCTUS2025051133Pending
- Vectors Expressing Hiv Antigens And Gm-csf And Related Methods For Generating An Immune ResponseApplication PCTUS2011025422Pending
- Single-dose Mva Vaccines For Protection Against MpoxApplication 63707632Pending
- Pan-betacoronavirus Vaccines And Uses ThereofApplication PCTUS2024021359Pending
- Pan-betacoronavirus Vaccines And Uses ThereofApplication 63457341Pending
- Pan-betacoronavirus Vaccines And Uses ThereofApplication 63454520Pending
- Vaccines And Uses Thereof To Induce An Immune Response To SARS-COV2Application PCTUS2021018033Pending
- Cancer Vaccine Compositions And Methods For Use ThereofApplication PCTUS2020035995Pending
- Vaccine And Use Thereof To Induce An Immune Response To 2019 Novel CoronavirusApplication 63026580Pending
- Vaccine And Use Thereof To Induce An Immune Response To 2019 Novel CoronavirusApplication 62992710Pending
- Vaccine And Use Thereof To Induce An Immune Response To 2019 Novel CoronavirusApplication 62977402Pending
- Vaccine And Use Thereof To Induce An Immune Response To 2019 Novel CoronavirusApplication 62976913Pending
- Methods And Compositions For Generating An Immune Response To Treat Or Prevent MalariaApplication PCTUS2018051652Pending
- Immuno-oncology Compositions And Methods For Use ThereofApplication PCTUS2018047907Pending
- Compositions And Methods For Generating An Immune Response To LasvApplication PCTUS2018042645Pending
- Multivalent Hiv Vaccine Boost Compositions And Methods Of UseApplication PCTUS2017018103Pending
- Compositions And Methods For Generating An Immune Response To A FlavivirusApplication PCTUS2017016013Pending
- Compositions And Methods For Generating An Immune Response To A Tumor Associated AntigenApplication PCTUS2017012704Pending
- Compositions And Methods For Generating An Immune Response To A Hemorrhagic Fever VirusApplication PCTUS2016013021Pending
Recent research by its founders
- RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques20230 cites
- A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection20228 cites
- Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine20212 cites
Related companies, and why
- TARGEPEUTICS, INC.Similar federal contract value in Biotech · $200K in contracts
- Celldex TherapeuticsSimilar federal contract value in Biotech · $199K in contracts
- Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts
- Angiocrine BioscienceSimilar federal contract value in Biotech · $189K in contracts
- Tenax TherapeuticsSimilar federal contract value in Biotech · $185K in contracts
- CANTATA BIO LLCSimilar federal contract value in Biotech · $182K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .